Latest Financial Performance News

Page 124 of 323
Cardiex Limited reported a 10% revenue increase in FY25, driven by new product launches and significant cost reductions, positioning the company for growth in FY26 with strong backing from C2 Ventures.
Ada Torres
Ada Torres
29 Aug 2025
Seafarms Group Limited reported a reduced loss of $11.7 million for FY2025, despite a 43% drop in revenue and ongoing legal challenges surrounding Project Sea Dragon. Production setbacks from flooding and subdued market demand weighed heavily on results.
Ada Torres
Ada Torres
29 Aug 2025
EVE Health Group has reported a 19% decline in revenue and a 17% increase in net loss for the financial year ended June 2025, highlighting ongoing challenges in its health and wellness segments.
Ada Torres
Ada Torres
29 Aug 2025
Spectur Limited reported a 6% revenue increase to $8.7 million and slashed its net loss by 70% to $779,000 in FY25, driven by operational restructuring and a shift toward recurring revenue streams.
Sophie Babbage
Sophie Babbage
29 Aug 2025
Equity Story Group reported a 9.1% revenue increase driven by its Securities division and reduced its net loss by 14.5% for FY2025. However, the company’s net liabilities grew and cash reserves sharply declined, raising questions about its financial footing.
Claire Turing
Claire Turing
29 Aug 2025
Coventry Group Ltd reported a 1.7% revenue decline and a 40.9% drop in EBITDA for FY25, prompting a major restructuring and a bullish FY26 earnings target above $20 million.
Victor Sage
Victor Sage
29 Aug 2025
Coventry Group reports a challenging FY25 with a statutory loss driven by ERP implementation costs and asset impairments, while setting ambitious EBITDA targets for FY26 under refreshed leadership.
Victor Sage
Victor Sage
29 Aug 2025
Coventry Group Ltd reported a challenging FY25 with a 1.7% revenue decline and a 40.9% drop in underlying EBITDA, culminating in a $29.6 million net loss. The company is now targeting over $20 million EBITDA in FY26 through aggressive cost reductions and operational recalibration.
Victor Sage
Victor Sage
29 Aug 2025
Cambium Bio reported a $3.84 million loss for FY25 but secured critical FDA approvals and ethics clearances to initiate Phase 3 trials of Elate Ocular®, supported by a $2.12 million capital raise.
Ada Torres
Ada Torres
29 Aug 2025
8common Limited reported a significant narrowing of its net loss for FY25 alongside a 16% growth in SaaS revenue and improved gross margins, positioning the company for profitability in FY26.
Sophie Babbage
Sophie Babbage
29 Aug 2025
Mustera Property Group reports an 82% plunge in revenue and a net loss of $2.6 million for the year ended June 2025, marking a stark reversal from the prior year’s profit.
Eva Park
Eva Park
29 Aug 2025
1414 Degrees Ltd reported a widened net loss of $3.34 million for FY25 while advancing its thermal energy storage and hydrogen reactor technologies, supported by fresh equity and government grants.
Maxwell Dee
Maxwell Dee
29 Aug 2025